TP53 mutations in older adults with acute myeloid leukemia

Masamitsu Yanada, Yukiya Yamamoto, Sachiko Iba, Akinao Okamoto, Yoko Inaguma, Masutaka Tokuda, Satoko Morishima, Tadaharu Kanie, Shuichi Mizuta, Yoshiki Akatsuka, Masataka Okamoto, Nobuhiko Emi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The net benefits of induction therapy for older adults with acute myeloid leukemia (AML) remain controversial. Because AML in older adults is a heterogeneous disease, it is important to identify those who are unlikely to benefit from induction therapy based on information available at the initial assessment. We used next-generation sequencing to analyze TP53 mutation status in AML patients aged 60 years or older, and evaluated its effects on outcomes. TP53 mutations were detected in 12 of 77 patients (16 %), and there was a significant association between TP53 mutations and monosomal karyotype. Patients with TP53 mutations had significantly worse survival than those without (P = 0.009), and multivariate analysis identified TP53 mutation status as the most significant prognostic factor for survival. Neverthelsess, TP53-mutated patients had a 42 % chance of complete remission and a median survival of 8.0 months, which compares favorably with those who did not undergo induction therapy, even in the short term. These results suggest that screening for TP53 mutations at diagnosis is useful for identifying older adults with AML who are least likely to respond to chemotherapy, although the presence of this mutation alone does not seem to justify rejecting induction therapy.

Original languageEnglish
Pages (from-to)429-435
Number of pages7
JournalInternational Journal of Hematology
Volume103
Issue number4
DOIs
Publication statusPublished - 01-04-2016

Fingerprint

Acute Myeloid Leukemia
Mutation
Survival
Therapeutics
Karyotype
Multivariate Analysis
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Yanada, M., Yamamoto, Y., Iba, S., Okamoto, A., Inaguma, Y., Tokuda, M., ... Emi, N. (2016). TP53 mutations in older adults with acute myeloid leukemia. International Journal of Hematology, 103(4), 429-435. https://doi.org/10.1007/s12185-016-1942-1
Yanada, Masamitsu ; Yamamoto, Yukiya ; Iba, Sachiko ; Okamoto, Akinao ; Inaguma, Yoko ; Tokuda, Masutaka ; Morishima, Satoko ; Kanie, Tadaharu ; Mizuta, Shuichi ; Akatsuka, Yoshiki ; Okamoto, Masataka ; Emi, Nobuhiko. / TP53 mutations in older adults with acute myeloid leukemia. In: International Journal of Hematology. 2016 ; Vol. 103, No. 4. pp. 429-435.
@article{6ccbbde0eda4421e83fc7c74317ce2a7,
title = "TP53 mutations in older adults with acute myeloid leukemia",
abstract = "The net benefits of induction therapy for older adults with acute myeloid leukemia (AML) remain controversial. Because AML in older adults is a heterogeneous disease, it is important to identify those who are unlikely to benefit from induction therapy based on information available at the initial assessment. We used next-generation sequencing to analyze TP53 mutation status in AML patients aged 60 years or older, and evaluated its effects on outcomes. TP53 mutations were detected in 12 of 77 patients (16 {\%}), and there was a significant association between TP53 mutations and monosomal karyotype. Patients with TP53 mutations had significantly worse survival than those without (P = 0.009), and multivariate analysis identified TP53 mutation status as the most significant prognostic factor for survival. Neverthelsess, TP53-mutated patients had a 42 {\%} chance of complete remission and a median survival of 8.0 months, which compares favorably with those who did not undergo induction therapy, even in the short term. These results suggest that screening for TP53 mutations at diagnosis is useful for identifying older adults with AML who are least likely to respond to chemotherapy, although the presence of this mutation alone does not seem to justify rejecting induction therapy.",
author = "Masamitsu Yanada and Yukiya Yamamoto and Sachiko Iba and Akinao Okamoto and Yoko Inaguma and Masutaka Tokuda and Satoko Morishima and Tadaharu Kanie and Shuichi Mizuta and Yoshiki Akatsuka and Masataka Okamoto and Nobuhiko Emi",
year = "2016",
month = "4",
day = "1",
doi = "10.1007/s12185-016-1942-1",
language = "English",
volume = "103",
pages = "429--435",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "4",

}

Yanada, M, Yamamoto, Y, Iba, S, Okamoto, A, Inaguma, Y, Tokuda, M, Morishima, S, Kanie, T, Mizuta, S, Akatsuka, Y, Okamoto, M & Emi, N 2016, ' TP53 mutations in older adults with acute myeloid leukemia', International Journal of Hematology, vol. 103, no. 4, pp. 429-435. https://doi.org/10.1007/s12185-016-1942-1

TP53 mutations in older adults with acute myeloid leukemia. / Yanada, Masamitsu; Yamamoto, Yukiya; Iba, Sachiko; Okamoto, Akinao; Inaguma, Yoko; Tokuda, Masutaka; Morishima, Satoko; Kanie, Tadaharu; Mizuta, Shuichi; Akatsuka, Yoshiki; Okamoto, Masataka; Emi, Nobuhiko.

In: International Journal of Hematology, Vol. 103, No. 4, 01.04.2016, p. 429-435.

Research output: Contribution to journalArticle

TY - JOUR

T1 - TP53 mutations in older adults with acute myeloid leukemia

AU - Yanada, Masamitsu

AU - Yamamoto, Yukiya

AU - Iba, Sachiko

AU - Okamoto, Akinao

AU - Inaguma, Yoko

AU - Tokuda, Masutaka

AU - Morishima, Satoko

AU - Kanie, Tadaharu

AU - Mizuta, Shuichi

AU - Akatsuka, Yoshiki

AU - Okamoto, Masataka

AU - Emi, Nobuhiko

PY - 2016/4/1

Y1 - 2016/4/1

N2 - The net benefits of induction therapy for older adults with acute myeloid leukemia (AML) remain controversial. Because AML in older adults is a heterogeneous disease, it is important to identify those who are unlikely to benefit from induction therapy based on information available at the initial assessment. We used next-generation sequencing to analyze TP53 mutation status in AML patients aged 60 years or older, and evaluated its effects on outcomes. TP53 mutations were detected in 12 of 77 patients (16 %), and there was a significant association between TP53 mutations and monosomal karyotype. Patients with TP53 mutations had significantly worse survival than those without (P = 0.009), and multivariate analysis identified TP53 mutation status as the most significant prognostic factor for survival. Neverthelsess, TP53-mutated patients had a 42 % chance of complete remission and a median survival of 8.0 months, which compares favorably with those who did not undergo induction therapy, even in the short term. These results suggest that screening for TP53 mutations at diagnosis is useful for identifying older adults with AML who are least likely to respond to chemotherapy, although the presence of this mutation alone does not seem to justify rejecting induction therapy.

AB - The net benefits of induction therapy for older adults with acute myeloid leukemia (AML) remain controversial. Because AML in older adults is a heterogeneous disease, it is important to identify those who are unlikely to benefit from induction therapy based on information available at the initial assessment. We used next-generation sequencing to analyze TP53 mutation status in AML patients aged 60 years or older, and evaluated its effects on outcomes. TP53 mutations were detected in 12 of 77 patients (16 %), and there was a significant association between TP53 mutations and monosomal karyotype. Patients with TP53 mutations had significantly worse survival than those without (P = 0.009), and multivariate analysis identified TP53 mutation status as the most significant prognostic factor for survival. Neverthelsess, TP53-mutated patients had a 42 % chance of complete remission and a median survival of 8.0 months, which compares favorably with those who did not undergo induction therapy, even in the short term. These results suggest that screening for TP53 mutations at diagnosis is useful for identifying older adults with AML who are least likely to respond to chemotherapy, although the presence of this mutation alone does not seem to justify rejecting induction therapy.

UR - http://www.scopus.com/inward/record.url?scp=84961613498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961613498&partnerID=8YFLogxK

U2 - 10.1007/s12185-016-1942-1

DO - 10.1007/s12185-016-1942-1

M3 - Article

VL - 103

SP - 429

EP - 435

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 4

ER -